Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|May 17, 2015
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studiesBrian Rini, Audrey Goddard, Dejan Knezevic, et al.
European Urology|January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT TrialRobert J Motzer, Paul Russo, Naomi Haas, et al.
The Oncologist|March 14, 2023
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, et al.
JCO Clinical Cancer Informatics|January 19, 2019
Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response EvaluationBrian C Allen, Edward Florez, Reza Sirous, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma settingAngela Meade, Bhavna Oza, Eleni Frangou, et al.
Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.
Pageof 10